| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | NaN | 1,003,904 | 1,948,271 | 206,233 |
| Cash and cash equivalents | 5,857,024 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | 890,149 | 55,102 | 419,421 | 783,189 |
| Inventories | 369,974 | 253,160 | 35,437 | NaN |
| Total current assets | 7,117,147 | 1,312,166 | 2,403,129 | 989,422 |
| Total assets | 7,117,147 | 1,312,166 | 2,403,129 | 989,422 |
| Other current liabilities | NaN | NaN | NaN | 0 |
| Notes payable related party-Related Party | NaN | 885,564 | 885,564 | 1,331,357 |
| Accounts payable | 857,925 | 1,014,377 | 1,060,889 | 1,351,639 |
| Loan and transfer notes payable | NaN | NaN | NaN | 499,214 |
| Subscription agreement loans | NaN | 1,500,000 | 1,500,000 | 2,025,344 |
| Convertible note | NaN | 1,290,476 | 4,739,965 | 3,617,508 |
| Accrued expenses | 441,614 | 1,008,569 | 266,930 | 378,181 |
| Due to affiliate-Affiliates | 353,679 | 353,679 | 353,679 | 353,679 |
| Promissory note fee related party-Related Party | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 |
| Derivative liability | NaN | 40,954 | 3,554,265 | NaN |
| Loan and transfer notes payable related party-Related Party | 499,214 | 499,214 | 499,214 | NaN |
| Total current liabilities | 3,152,432 | 7,592,833 | 13,860,506 | 10,556,922 |
| Forward purchase agreement liability | 96,252 | 95,662 | 9,901 | 49,285 |
| Total liabilities | 3,248,684 | 7,688,495 | 13,870,407 | 10,606,207 |
| Series a convertible preferred stock, 25,000 shares as designated, 0.0001 par value 13,750 and 0 shares issued or outstanding at march 31, 2026 and december 31, 2025, respectively | 1 | NaN | NaN | NaN |
| Common stock 0.0001 par value 490,000,000 shares authorized 167,470 and 117,780 issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 17 | 353 | 4,953 | 4,953 |
| Additional paid-in capital | 34,349,418 | 20,881,399 | 11,078,116 | 11,078,116 |
| Accumulated deficit | -30,480,973 | -27,258,081 | -22,550,347 | -20,699,854 |
| Total stockholders equity (deficit) | 3,868,463 | -6,376,329 | -11,467,278 | -9,616,785 |
| Total liabilities and stockholders equity (deficit) | 7,117,147 | 1,312,166 | 2,403,129 | 989,422 |
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)